News zum Sektor Gesundheit aus Australien

 

HeraMED Phase 1 Lee Health digital obstetrics pilot validates HeraCARE; 44 patients, 92% adopt digital path; Phase 2 decision soon....

With more than 600k average monthly users on the HotCopper forums, each…...

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial....

Would the Sage from Omaha be interested in Australia's fallen giant? The post Would Warren Buffett buy CSL shares? appeared first on The Motley Fool Australia....

CLEVELAND, July 13, 2026 /PRNewswire/ -- Cleveland Medical Devices Inc. announced that proceedings before the Patent Trial and Appeal Board have now produced favorable outcomes for Cleveland Medical Devices in five of the six inter partes review petitions filed by ResMed against patents......

Während sich die internationalen Aktienmärkte auf hohem Niveau bewegen, rücken Einzeltitel mit besonderem Kurspotenzial stärker in den Fokus. Almonty Industries, Deutsche Bank und Bayer stehen dabei für drei völlig unterschiedliche Investmentstorys. Almonty profitiert vom weltweiten Wettbewerb um kritische Rohstoffe und hat mit dem Produktionshochlauf der Sangdong-Mine in Südkorea einen entscheidenden Meilenstein erreicht. Das Unternehmen könnte […] The post Amonty, Deutsche Bank oder Bayer: Wer überrascht im zweiten Halbjahr? first appeared on sharedeals.de....

SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced a significant positive update of the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co. Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and chemotherapy as 1st line therapy for advanced/metastatic non-small cell lung cancer (1L NSCLC) in 51 evaluable non-squamous patients....

Fully rechargeable: First fully rechargeable active bone conduction sound processor, with up to 30 hours of battery life on a single charge. †,7-9 Improved power and sound quality: Improved clarity and sound quality, enhanced by the new signal processing platform and powerful lithium-ion......

CSL Group übernimmt IoTM Solutions zur Stärkung der globalen eSIM-Orchestrierung...

Adding proven SIM management scale and 100+ operator access to accelerate SGP.32 eSIM readiness LONDON, July 13, 2026 /PRNewswire/ -- CSL Group, the leading global provider of Critical Connectivity®, has acquired IoTM Solutions Ltd, creating a global platform for resilient, multi-carrier......

Can CSL shares continue their comeback? The post CSL shares are up 35% since early June. Is the recovery here to stay? appeared first on The Motley Fool Australia....

This biotechnology company just became less risky according to Bell Potter. The post Why Mesoblast shares could double in value appeared first on The Motley Fool Australia....

Here's what John Athanasiou from Red Leaf Securities thinks of these three ASX 200 shares. The post Buy, hold, sell: TechnologyOne, Pro Medicus, PLS Group shares appeared first on The Motley Fool Australia....

Brokers see long-term value despite differing views on near-term upside. The post Where could CSL shares go next? Here's what brokers are predicting appeared first on The Motley Fool Australia....

RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health....

The Bulls N' Bears ASX Runner of the Week is… Argent BioPharma, striking a smart licensing deal for its CannEpil epilepsy drug that wipes out a major debt overhang while retaining blue-sky through royalties....

The Bulls N' Bears ASX Runner of the Week is… Argent BioPharma, striking a smart licensing deal for its CannEpil epilepsy drug that wipes out a major debt overhang while retaining blue-sky through royalties....

Can the US growth story drive the ASX star back to records? The post Up 1,636%, but can 4DMedical shares reclaim their record high? appeared first on The Motley Fool Australia....

Brokers retained a positive view on BHP, Pro Medicus, Telstra, Coles, and others this week.  The post 9 ASX 200 shares with reiterated buy calls this week appeared first on The Motley Fool Australia....

Ryoncil® uptake has exceeded initial projections The post Mesoblast shares: Q4 earnings top projections appeared first on The Motley Fool Australia....